» Articles » PMID: 37101029

[Obesity and Type 2 diabetes (Update 2023)]

Overview
Publisher Springer
Specialty General Medicine
Date 2023 Apr 26
PMID 37101029
Authors
Affiliations
Soon will be listed here.
Abstract

The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept.

Citing Articles

Vitamin D Alleviates Type 2 Diabetes Mellitus by Mitigating Oxidative Stress-Induced Pancreatic β-Cell Impairment.

Liu J, Zhang Y, Shi D, He C, Xia G Exp Clin Endocrinol Diabetes. 2023; 131(12):656-666.

PMID: 37935388 PMC: 10700019. DOI: 10.1055/a-2191-9969.


Enhancing Muscle Intracellular Ca Homeostasis and Glucose Uptake: Passive Pulsatile Shear Stress Treatment in Type 2 Diabetes.

Uryash A, Umlas J, Mijares A, Adams J, Lopez J Biomedicines. 2023; 11(10).

PMID: 37892970 PMC: 10604129. DOI: 10.3390/biomedicines11102596.

References
1.
Hossain P, Kawar B, El Nahas M . Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007; 356(3):213-5. DOI: 10.1056/NEJMp068177. View

2.
Oldridge N, Stump T, Nothwehr F, Clark D . Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol. 2001; 54(9):928-34. DOI: 10.1016/s0895-4356(01)00350-x. View

3.
Fruhbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert J . Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013; 6(2):117-20. PMC: 5644725. DOI: 10.1159/000350627. View

4.
Finucane M, Stevens G, Cowan M, Danaei G, Lin J, Paciorek C . National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011; 377(9765):557-67. PMC: 4472365. DOI: 10.1016/S0140-6736(10)62037-5. View

5.
Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View